Literature DB >> 22751858

[Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus].

S Krengel1, I Satzger, M Alter, A Kapp, R Gutzmer.   

Abstract

Iatrogenic Kaposi sarcomas (KS) in organ transplant recipients are often treated by switching immunosuppressive therapy to an mTOR inhibitor, such as sirolimus or everolimus, as these have immunosuppressive as well as anti-tumor effects. We report on an 80-year-old male patient who developed a disseminated cutaneous KS during therapy with prednisone and azathioprine for myasthenia gravis. After discontinuation of azathioprine therapy and despite continuing therapy with cortisone, the KS progressed and autoantibody levels against the nicotinic acetylcholine receptor increased. During the administration of everolimus, a long-term near-complete remission of KS and a decrease in autoantibodies took place. This case study illustrates that even in non-organ transplant patients with iatrogenic KS, switching to immunosuppressive therapy using an mTOR inhibitor can be beneficial.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751858     DOI: 10.1007/s00105-011-2274-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  26 in total

1.  Development of multiple malignancies after immunosuppression in a patient with Wegener's granulomatosis.

Authors:  Mari Hoff; Erik Rødevand
Journal:  Rheumatol Int       Date:  2005-01-20       Impact factor: 2.631

2.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

3.  Conjunctival Kaposi's sarcoma in a patient with myasthenia gravis.

Authors:  J J Bedrick; P J Savino; N J Schatz
Journal:  Arch Ophthalmol       Date:  1981-09

4.  Sirolimus conversion for patients with posttransplant Kaposi's sarcoma.

Authors:  C Lebbé; S Euvrard; B Barrou; C Pouteil-Noble; J L Garnier; D Glotz; C Legendre; C Francès
Journal:  Am J Transplant       Date:  2006-06-19       Impact factor: 8.086

Review 5.  Kaposi's sarcoma in rheumatic diseases.

Authors:  Worawit Louthrenoo; Nuntana Kasitanon; Pongsak Mahanuphab; Lertlakana Bhoopat; Sumitra Thongprasert
Journal:  Semin Arthritis Rheum       Date:  2003-04       Impact factor: 5.532

6.  Conversion to sirolimus in renal transplant patients with tumors.

Authors:  A Sánchez-Fructuoso; J Conesa; I Perez Flores; N Ridao; N Calvo; D Prats; A Rodríguez; A Barrientos
Journal:  Transplant Proc       Date:  2006-10       Impact factor: 1.066

7.  Reccurence of Kaposi's sarcoma after increased exposure to sirolimus.

Authors:  Maria Boratyńska; Sławomir C Zmonarski; Marian Klinger
Journal:  Int Immunopharmacol       Date:  2006-10-18       Impact factor: 4.932

8.  KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case.

Authors:  Magali Svrcek; Emmanuel Tiret; Malika Bennis; Philippe Guyot; Jean-François Fléjou
Journal:  Dis Colon Rectum       Date:  2009-01       Impact factor: 4.585

9.  Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.

Authors:  Josep M Campistol; Alex Gutierrez-Dalmau; J Vicente Torregrosa
Journal:  Transplantation       Date:  2004-03-15       Impact factor: 4.939

Review 10.  The role of mTOR inhibitors in the management of posttransplant malignancy.

Authors:  Anthony P Monaco
Journal:  Transplantation       Date:  2009-01-27       Impact factor: 4.939

View more
  4 in total

Review 1.  Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update.

Authors:  Hallvard Holdaas; Paolo De Simone; Andreas Zuckermann
Journal:  J Transplant       Date:  2016-10-11

2.  Rapamycin alleviates inflammation and muscle weakness, while altering the Treg/Th17 balance in a rat model of myasthenia gravis.

Authors:  Feng Jing; Fei Yang; Fang Cui; Zhaohui Chen; Li Ling; Xusheng Huang
Journal:  Biosci Rep       Date:  2017-07-16       Impact factor: 3.840

3.  Effects of Mitophagy on Regulatory T Cell Function in Patients With Myasthenia Gravis.

Authors:  Na Wang; Jiang Yuan; Md Rezaul Karim; Ping Zhong; Yan-Peng Sun; Hong-Yan Zhang; Yun-Fu Wang
Journal:  Front Neurol       Date:  2020-04-07       Impact factor: 4.003

Review 4.  Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases.

Authors:  Carmen Rodriguez-Cerdeira; Elena Sanchez-Blanco; Alberto Molares-Vila
Journal:  Mediators Inflamm       Date:  2012-11-01       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.